BioVie Inc. (BIVI): Price and Financial Metrics


BioVie Inc. (BIVI): $5.05

0.02 (+0.40%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add BIVI to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

BIVI Stock Price Chart Interactive Chart >

Price chart for BIVI

BIVI Price/Volume Stats

Current price $5.05 52-week high $14.38
Prev. close $5.03 52-week low $1.33
Day low $4.88 Volume 213,733
Day high $5.17 Avg. volume 382,767
50-day MA $6.53 Dividend yield N/A
200-day MA $3.71 Market Cap 154.19M

BioVie Inc. (BIVI) Company Bio


BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. It develops BIV201, which completed Phase 2a clinical trial for the treatment of ascites due to chronic liver cirrhosis. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was founded in 2013 and is based in Santa Monica, California.


BIVI Latest News Stream


Event/Time News Detail
Loading, please wait...

BIVI Latest Social Stream


Loading social stream, please wait...

View Full BIVI Social Stream

Latest BIVI News From Around the Web

Below are the latest news stories about BIOVIE INC that investors may wish to consider to help them evaluate BIVI as an investment opportunity.

RedChip CEO Dave Gentry Invited to Join Forbes Business Council

RedChip Companies is pleased to announce its CEO, Dave Gentry, was recently welcomed as a member of the Forbes Business Council.

Yahoo | January 25, 2023

Why Shares of BioVie Rose 15.3% in December

Shares of biotech BioVie (NASDAQ: BIVI) rose 15.3% in December, according to data provided by S&P Global Market Intelligence. The clinical-stage biotech's stock jumped after the company announced on Dec. 5 that its candidate therapy NE3107 had shown positive results in studies on both Parkinson's disease and Alzheimer's disease. In one of the phase 2 trials, 88.9% of Parkinson's disease patients 70 or older who were treated with NE3107 in combination with levodopa (the current standard of care for Parkinson's) showed improvements of greater than 30% on their UPDRS Part 3 score -- a key measurement of motor function -- compared to just 63.6% of patients treated with levodopa alone.

Yahoo | January 5, 2023

Beat the Market Like Zacks: JPMorgan Chase, Oracle, BioVie in Focus

Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.

Yahoo | January 3, 2023

BioVie Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)

RedChip Companies will air a new interview BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, on The RedChip Money Report® on Bloomberg TV, this Saturday, Dec. 31, at 7 p.m. Eastern Time (ET).

Yahoo | December 29, 2022

Does BioVie Inc. (BIVI) Have the Potential to Rally 52% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 52.1% in BioVie Inc. (BIVI). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Yahoo | December 27, 2022

Read More 'BIVI' Stories Here

BIVI Price Returns

1-mo -19.20%
3-mo 28.50%
6-mo 134.88%
1-year 61.86%
3-year N/A
5-year -49.56%
YTD -35.01%
2022 72.67%
2021 -74.02%
2020 394.86%
2019 N/A
2018 0.00%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6173 seconds.